Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells

Valeria Bica1,2, Anna Francesca Pacilè1, Martin Boettcher3,4

  • 1Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133, Rome, Italy.

Leukemia
|June 9, 2026
PubMed

Insights

The FLT3-ITD insertion site in acute myeloid leukemia dictates drug sensitivity. Lipid restriction targets FLT3 trafficking, overcoming resistance to tyrosine kinase inhibitors (TKIs) like midostaurin.

Area of Science:

  • Hematology
  • Molecular Biology
  • Cancer Research

Background:

  • FLT3 internal tandem duplications (ITDs) are common in acute myeloid leukemia (AML).
  • The insertion site of FLT3-ITD influences sensitivity to tyrosine kinase inhibitors (TKIs).
  • Patients with FLT3-ITD in the tyrosine kinase domain (TKD) have limited therapeutic options.

Purpose of the Study:

  • To investigate the molecular mechanisms behind differential TKI sensitivity in FLT3-ITD AML.
  • To identify novel therapeutic strategies for overcoming TKI resistance in FLT3-ITD AML.

Main Methods:

  • Integrated high-resolution mass spectrometry-based (phospho)proteomics with subcellular fractionation.
  • Functional analyses of autophagy and mitochondrial metabolism.
  • Lipid restriction assays and assessment of FLT3 trafficking and cell viability.

Main Results:

  • Midostaurin treatment caused significant subcellular redistribution of proteins involved in cell cycle, autophagy, and metabolism.
  • The FLT3-ITD insertion site modulated autophagy response and mitochondrial metabolism.
  • Lipid restriction enhanced FLT3 plasma membrane trafficking, reduced cell viability, and restored midostaurin sensitivity in resistant cells.

Conclusions:

  • The FLT3-ITD insertion site drives coordinated remodeling of protein organization, autophagy, and metabolism.
  • Lipid-mediated control of FLT3 compartmentalization is a therapeutically actionable vulnerability in FLT3-ITD AML.
  • Targeting lipid metabolism offers a strategy to overcome TKI resistance in AML.

Related Concept Videos